A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety of SHR-1702 monotherapy or in combination with Camrelizumab among advanced solid tumor subjects.
Advanced Solid Tumor
DRUG: SHR-1702|DRUG: Camrelizumab
Number of Participants with DLTs, Approximately 28 Days
ORR: Percentage of Participants With a CR or PR, Approximately 2 years|Safety and tolerability of SHR -1702 using Common Terminology Criteria for Adverse Events., Dose Escalation Part -- Approximately 2 years|Immunogenicity as assessed by the presence of anti-drug antibodies, Approximately 2 years|Pharmacodynamic profile as assessed by receptor occupancy, Approximately 2 years|PK Parameter: Maximum Concentration (Cmax), Approximately 2 years|PK Parameter: AUC, 0 to infinity, Approximately 2 years|PK Parameter: Clearance (CL), Approximately 2 years|PK Parameter: Cmin at steady state (Cmin,ss), Approximately 2 years|PK Parameter: Cmax at steady state (Cmax, ss), Approximately 2 years|PK Parameter: terminal half-life (t1/2), Approximately 2 years
The purpose of this study is to evaluate the safety of SHR-1702 monotherapy or in combination with Camrelizumab among advanced solid tumor subjects.